Organigram Global (OGI) Non-Current Assets (2018 - 2025)
Organigram Global (OGI) reported Non-Current Assets of $201.5 million for Q3 2025, up 204.83% year-over-year from $66.1 million in Q3 2024, and up 204.83% quarter-over-quarter from -$192.2 million in Q3 2024.
Organigram Global (OGI) Non-Current Assets (2018 - 2025) Analysis & Trends
Organigram Global (OGI) has 8 years of Non-Current Assets data on file, last reported at $201.5 million in Q3 2025.
- Non-Current Assets for Q3 2025 came in at $201.5 million, up 204.83% year-over-year; the trailing twelve-month figure through Sep 2025 was -$279.2 million (up 59.56% YoY), and the FY2025 annual result was $201.5 million, up 204.52% from the prior year.
- Non-Current Assets advanced to $201.5 million in Q3 2025 per OGI's latest filing, from -$192.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $260.5 million in Q1 2021 and troughed at -$209.7 million in Q3 2021.
- A 5-year average of -$38.1 million and a median of -$144.2 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2025: Non-Current Assets slumped 167.97% in 2021, then jumped 204.83% in 2025.
- A 5-year view of Non-Current Assets shows it stood at -$209.7 million in 2021, then rose by 17.92% to -$172.1 million in 2022, then surged by 32.39% to -$116.3 million in 2023, then plunged by 65.21% to -$192.2 million in 2024, then soared by 204.83% to $201.5 million in 2025.
- Business Quant data shows OGI's Non-Current Assets at $201.5 million in Q3 2025, -$192.2 million in Q3 2024, and -$116.3 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.22 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.40 Bn |
| 10 | Organigram Global | 731.20 Mn | 673.26 Mn | 11.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 201.51 Mn |
| Sep 30, 2024 | -192.22 Mn |
| Sep 30, 2023 | -116.35 Mn |
| Aug 31, 2022 | -172.09 Mn |
| Aug 31, 2021 | -209.66 Mn |
| Feb 28, 2021 | 260.51 Mn |
| Nov 30, 2020 | 265.00 Mn |
| Aug 31, 2020 | 308.47 Mn |
| May 31, 2020 | 193.82 Mn |
| Feb 29, 2020 | 293.94 Mn |
| Nov 30, 2019 | 277.72 Mn |
| Aug 31, 2019 | 175.67 Mn |
| May 31, 2019 | 195.52 Mn |
| Aug 31, 2018 | 147.36 Mn |